Proctolin's role in neurally evoked contractions of the locust oviducts.
The effects of proctolin (RYLPT) on neurally evoked contractions of locust oviduct muscle were studied to examine the role of proctolin as a cotransmitter. Increasing the number of stimuli in a burst (from one to 30 stimuli) resulted in an increase in amplitude of contraction of locust oviduct muscle. Proctolin was capable of increasing the amplitude of neurally evoked contractions at lower-stimulus regimes (one- and two-stimulus bursts) but did not do so at higher-stimulus regimes (five- and 10-stimulus bursts). The effects of proctolin were dose dependent within the one- and two-stimulus regimes, with thresholds at 10(-9) M and maxima at 2.5 x 10(-8) M. Addition of proctolin increased the basal tonus and size of a postcontraction relaxation of the oviduct muscle in a dose-dependent manner during all stimulus regimes. However, the effect of proctolin on basal tonus and the postcontraction relaxation was much less at the higher stimulus regimes. Previously, several proctolin analogues have been tested for their ability to antagonize proctolin-induced contractions of the oviduct muscle. Since proctolin is proposed to be a cotransmitter at this neuromuscular junction, one of these analogues, cycloproctolin, was used to antagonize proctolin's effects on neurally evoked contractions. In the presence of the antagonist, the maximum amplitude induced by application of proctolin was decreased by 22.7%, while the proctolin-induced increase in basal tonus was decreased by 45.8%. Finally, the maximum increase in the size of the postcontraction relaxation caused by proctolin was lowered by 32.0%. The results of the present study show that exogenously applied proctolin is an excitant of the oviduct muscle at lower, rather than higher, stimulus regimes, and this latter inaction may be due to the corelease of endogenous proctolin during increased neural stimulation.
Noronha
K F
KF
Department of Biology, Erindale College, University of Toronto, Mississauga, Ontario, Canada.
Lange
A B
AB
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D005260:Female; D006110:Grasshoppers / Q000502:physiology*; D009119:Muscle Contraction / Q000502:physiology*; D009469:Neuromuscular Junction / Q000187:drug effects / Q000502:physiology; D009479:Neuropeptides; D018377:Neurotransmitter Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009842:Oligopeptides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010057:Oviducts / Q000294:innervation / Q000502:physiology; D010646:Phentolamine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D009842:Oligopeptides; C011536:proctolin; D010646:Phentolamine